Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 49Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Paclitaxel 162Fulvestrant 157Trastuzumab 156pembrolizumab 146Letrozole 137Carboplatin 118pertuzumab 104Capecitabine 104Specimen Handling 102Cyclophosphamide 102Anastrozole 90palbociclib 86abemaciclib 82Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 74trastuzumab deruxtecan 68Radiotherapy 62Biopsy 59Surveys and Questionnaires 55Gemcitabine 53130-nm albumin-bound paclitaxel 53olaparib 52sacituzumab govitecan 51Blood Specimen Collection 51Standard of Care 49Taxes 48eribulin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
enfortumab vedotin × Breast × 1 year × Clear all
NCT07287995 2026-04-23

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Recruiting
428 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡